These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28288370)

  • 21. An update on pharmacological approaches to neurodegenerative diseases.
    Scatena R; Martorana GE; Bottoni P; Botta G; Pastore P; Giardina B
    Expert Opin Investig Drugs; 2007 Jan; 16(1):59-72. PubMed ID: 17155854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Patent Advances for Neurodegenerative Disorders and its Treatment.
    Kumar B; Sharma D
    Recent Pat Drug Deliv Formul; 2017; 11(3):158-172. PubMed ID: 29032765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Precision Small-Molecule Proneurotrophic Therapies for Neurodegenerative Diseases.
    Janssens J; Lu D; Ni B; Chadwick W; Siddiqui S; Azmi A; Etienne H; Jushaj A; van Gastel J; Martin B; Maudsley S
    Vitam Horm; 2017; 104():263-311. PubMed ID: 28215298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases.
    Heng BC; Aubel D; Fussenegger M
    Biotechnol Adv; 2013 Dec; 31(8):1676-94. PubMed ID: 23999358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases.
    Serafino A; Sferrazza G; Colini Baldeschi A; Nicotera G; Andreola F; Pittaluga E; Pierimarchi P
    Expert Opin Drug Discov; 2017 Feb; 12(2):169-186. PubMed ID: 27960558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits.
    Benetti F; Gustincich S; Legname G
    Expert Opin Drug Discov; 2012 Mar; 7(3):245-59. PubMed ID: 22468955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are astrocytes executive cells within the central nervous system?
    Sica RE; Caccuri R; Quarracino C; Capani F
    Arq Neuropsiquiatr; 2016 Aug; 74(8):671-8. PubMed ID: 27556379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.
    Nishi A; Shuto T
    Expert Opin Ther Targets; 2017 Mar; 21(3):259-272. PubMed ID: 28052701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metallothioneins and the central nervous system: from a deregulation in neurodegenerative diseases to the development of new therapeutic approaches.
    Bolognin S; Cozzi B; Zambenedetti P; Zatta P
    J Alzheimers Dis; 2014; 41(1):29-42. PubMed ID: 24577478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Therapeutic GPCRs for Psychiatric Disorders.
    Komatsu H
    Int J Mol Sci; 2015 Jun; 16(6):14109-21. PubMed ID: 26101869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Astrocytes in neurodegenerative disease.
    Phatnani H; Maniatis T
    Cold Spring Harb Perspect Biol; 2015 Apr; 7(6):. PubMed ID: 25877220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic potential of G-protein coupled receptors in Huntington's disease.
    Dowie MJ; Scotter EL; Molinari E; Glass M
    Pharmacol Ther; 2010 Nov; 128(2):305-23. PubMed ID: 20708032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting GRK5 for Treating Chronic Degenerative Diseases.
    Marzano F; Rapacciuolo A; Ferrara N; Rengo G; Koch WJ; Cannavo A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of glia phenotype modulators based on select glial function regulatory signaling pathways.
    Lee SH; Suk K
    Expert Opin Drug Discov; 2018 Jul; 13(7):627-641. PubMed ID: 29676181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders.
    Yang Y; Jiang S; Yan J; Li Y; Xin Z; Lin Y; Qu Y
    Cytokine Growth Factor Rev; 2015 Feb; 26(1):47-57. PubMed ID: 25280871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G protein-coupled receptors: abnormalities in signal transmission, disease states and pharmacotherapy.
    Zalewska M; Siara M; Sajewicz W
    Acta Pol Pharm; 2014; 71(2):229-43. PubMed ID: 25272642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.